鲁拉西酮和利培酮治疗精神分裂症的疗效对比  

Study on the Efficacy of Lurasidone and Risperidone in the treatment of Schizophrenia

作　　者：蔡洪斌 孙奎亮 杨晖 CAI Hongbin;SUN Kuiiang;YANG Hui(Zhoucun District Mental Health Center,Zibo 255300,China;Zibo City Zhoucun District Wangcun Town Center Health Center,Zibo 255300,China)

机构地区：[1]周村区精神卫生中心,山东淄博255300 [2]淄博市周村区王村镇中心卫生院,山东淄博255300

出　　处：《中国医药指南》2023年第22期95-97,共3页Guide of China Medicine

摘　　要：目的 比较鲁拉西酮与利培酮治疗精神分裂症(SZ)的疗效差异。方法 收集2022年1~12月在淄博市周村区精神病医院住院的18~60岁符合ICD-10SZ诊断标准的患者50例,患者近6个月内处于未服药状态。完成基线体质量、BMI、血压、血脂、血糖、血细胞、肝肾功能、肌张力等实验室及体检检查。使用阳性和阴性症状量表(PANSS)进行SZ严重程度基线评估。将患者随机分为两组,鲁拉西酮组和利培酮组,每组25例患者,分别给予鲁拉西酮(最大剂量80 mg/d)和利培酮(最大剂量4 mg/d)治疗,在治疗第4周和第6周结束时使用PANSS评定SZ严重程度;在第6周结束时测量体质量、计算体质量指数(BMI)并进行必要的实验室检查来记录和监测药物不良反应。结果 两组在第4周、第6周结束时PANSS阳性症状量表分、阴性症状量表分及总分均显著下降(P <0.001),但组间无差异(P> 0.05);在治疗第6周结束时,鲁拉西酮组的体质量(P <0.001)和BMI增加程度比利培酮组小(P <0.001),鲁拉西酮组的其他不良反应例数少。结论 在降低PANSS评分方面,鲁拉西酮与利培酮同样有效,但鲁拉西酮对SZ患者的体质量和BMI影响较利培酮更小。Objective To study the efficacy of lurasidone and risperidone in the treatment of schizophrenia.Methods From January 2022 to December 2022,50 patients aged 18 to 60 years who met the ICD-10 diagnostic criteria for schizophrenia were hospitalized in the Zhoucun District Psychiatric Hospital of Zibo City.The patients were in a non medication state for nearly 6 months.Complete baseline body weight,BMI,blood pressure,blood lipids,blood glucose,blood cells,liver and kidney function,muscle tone,and other laboratory and physical examinations.Baseline assessment of the severity of schizophrenia was conducted using the Positive and Negative Symptom Scale(PANSS).The patients were randomly divided into two groups(lurasidone group and risperidone group),with 25 patients in each group.They were treated with lurasidone(maximum dose 80 mg/day)and risperidone(maximum dose 4 mg/day),respectively.At the end of the fourth and sixth weeks of treatment,the severity of schizophrenia was assessed using PANSS;At the end of week 6,body weight was measured,body mass index(BMI)was calculated,and necessary laboratory tests were performed to record and monitor adverse drug reactions.Results At the end of the 4th and 6th weeks,the scores of the PANSS positive symptom scale,the PANSS negative symptom scale,and the total score were significantly decreased in the two groups(P<0.001),but there was no difference between the groups(P>0.05).At the end of the 6th week of treatment,the weight(P<0.001)and BMI increase in the lurasidone group were smaller than those in the risperidone group(P<0.001),and the number of other adverse reactions in the lurasidone group was smaller.Conclusion Lurasidone is equally effective as risperidone in reducing PANSS scores,but its body weight and BMI increase is less than that of risperidone.

关 键 词：精神分裂症 鲁拉西酮 利培酮 阳性和阴性综合征量表 体质量 体质量指数 

分 类 号：R749.3[医药卫生—神经病学与精神病学]